Skip to content
Menu
Press Releases
Filter Releases
 
EMERYVILLE, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the first quarter ended March 31, 2017. "In the first quarter, we continued preparing for the potential approval and commercialization of ADS-5102, which, if approved, will be the first ...
EMERYVILLE, Calif., May 05, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported the grant of inducement awards to its new Chief Operating Officer, Richard A. King. The compensation committee of the company's board of directors granted Mr. King a stock option to purchase 168,750 shares of the company's common stock, ...
May 5, 2017 General Releases HTML PDF
EMERYVILLE, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2017 financial results on Tuesday, May 9, 2017 after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financi...
May 2, 2017 General Releases HTML PDF
EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Richard A. King as Chief Operating Officer, reporting to Gregory T. Went, Ph.D., Chairman and Chief Executive Officer. Mr. King will be responsible for leading the Company's commercial organization and its establish...
Apr 27, 2017 General Releases HTML PDF
-- Results presented in oral platform and poster sessions at the 69th American Academy of Neurology (AAN) Annual Meeting -- -- Results from the pooled analysis showed approximately twice as many ADS-5102 treated patients as placebo treated patients reported complete resolution of ON time with troublesome dyskinesia and OFF time at 12 weeks -- ...
Apr 24, 2017 General Releases HTML PDF
EMERYVILLE, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced details regarding upcoming oral platform and poster presentations highlighting pooled data from the Phase 3 EASE LID and EASE LID 3 clinical trials of ADS-5102 (amantadine) extended-release capsules for the treatment of levodopa-induc...
Apr 18, 2017 General Releases HTML PDF
EMERYVILLE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced details regarding a poster presentation highlighting data from EASE LID, its Phase 3 efficacy study of ADS-5102 (amantadine hydrochloride) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) in patients wi...
Mar 28, 2017 General Releases HTML PDF
EMERYVILLE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is scheduled to present at the Needham Healthcare Conference in New York on Tuesday, April 4, 2017 at 10:40 a.m. Eastern Time. The presentation will be we...
Mar 28, 2017 General Releases HTML PDF
EMERYVILLE, Calif., March 10, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted a new employee a stock option to purchase 26,250 shares of the company's common stock, at a per share exercise price of $16.97, the closing trading price on M...
Mar 10, 2017 General Releases HTML PDF
EMERYVILLE, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is scheduled to present at the Cowen and Company Health Care Conference in Boston on Monday, March 6, 2017 at 2:00 p.m. Eastern Time. The presentation w...
Mar 1, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2016.  "We expect 2017 to be a pivotal year as we transform from an R&D-focused company to a commercial organization as we anticipate...
Feb 28, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of additional data from EASE LID 2, its Phase 3 open-label, long-term safety and efficacy study of ADS-5102 (amantadine hydrochloride) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) in...
Feb 28, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) will present results from its Phase 2 proof-of-concept study of ADS-5102 (amantadine hydrochloride) extended-release capsules for the treatment of walking impairment in patients with multiple sclerosis (MS) at the Americas Committee for Treatment and ...
Feb 17, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today outlines key business priorities for 2017, in addition to providing a review of 2016 achievements. "We expect 2017 to be a landmark year for Adamas," said Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceutical...
Jan 8, 2017 General Releases HTML PDF
-- PDUFA Action Date Set for August 24, 2017 --  -- If Approved, ADS-5102 will be the First and Only Medicine Approved for the Treatment of LID in Parkinson's Disease -- EMERYVILLE, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has accept...
Jan 6, 2017 General Releases HTML PDF